The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
18-Dec-13
$NA
Target:
Fidelis SeniorCare Inc. (Michigan Heath Plan)
Acquiror:
Centene Corporation
Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space
17-Jul-13
$600 million
Target:
Lincoln Benefit Life, a subsidiary of the Allstate Corporation
Acquiror:
Resolution Life Holdings
Advised the limited partners of Resolution Life L.P. in the proposed acquisition by its subsidiary, Resolution Life Holdings, Inc., of Lincoln Benefit Life for $600mm
12-Jun-13
$893 million
Target:
A$1.6bn non-core loan portfolio
Acquiror:
Goldman Sachs Group. Inc.
Advised Suncorp Group Ltd (ASX:SUN), a leading general insurance, retail banking and life insurance group in Australia and New Zealand, on the sale of a A$1.6bn portfolio of performing and non-performing (corporate and property) loans to Goldman Sachs Group Inc., an American multinational investment banking firm
31-May-13
$57 million
Target:
d-cyphaTrade Limited
Acquiror:
Australian Securities Exchange (ASX)
Advised Transpower New Zealand, the state owned owner-operator of New Zealand’s electricity distribution network on the sale of its wholly owned subsidiary d-cyphaTrade Limited to the Australian Securities Exchange. d-cyphaTrade specializes in the design and marketing of Australian electricity derivatives traded on the ASX24 derivatives platform
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
08-May-13
$110 million
Target:
Healthcare Finance Group, LLC
Acquiror:
Fifth Street Finance Corp.
Advised Fifth Street Finance Corp., a specialty finance company with approximately $2 billion of assets under management, on the acquisition of Healthcare Finance Group, LLC, a specialty lender providing asset-based lending and term loan products to the healthcare industry
19-Dec-12
$100 million
Target:
Thiele Kaolin Company
Advised Thiele Kaolin Company, a miner and processor of kaolin clay, on a range of strategic options, resulting in a leveraged recapitalization and special dividend
11-Dec-12
$51.6 billion
Target:
American International Group (AIG)
Advised the United States Department of the Treasury (“UST”) on the full reduction of its 92% ownership stake in the insurer through numerous Secondary Public Offering Transactions
30-Oct-12
$834 million
Target:
Investments of AP Alternative Assets, L.P.
Acquiror:
Athene Holding Ltd.
Advised the Special Committee of the Conflicts Committee of the Board of Directors of Athene Holding Ltd. in connection with the purchase of non-cash investment assets of AP Alternative Assets L.P.
23-Oct-12
$5.7 billion
Target:
Target Corporation’s REDcard credit card assets
Acquiror:
The Toronto-Dominion Bank Group
Advised The Toronto-Dominion Bank Group on its acquisition of Target Corporation’s REDcard credit card assets
27-Sep-12
$1.5 billion
Target:
The Hartford’s Individual Life Insurance Business
Acquiror:
Prudential Financial, Inc.
Advised The Hartford, a leading provider of insurance and wealth management services, on the divestiture of its Individual Life Insurance Business to Prudential Financial, Inc.
04-Sep-12
$600 million
Target:
The Hartford’s Retirement Plans Group
Acquiror:
Massachusetts Mutual Life Insurance Company
Advised The Hartford, a leading provider of insurance and wealth management services, on the divestiture of its Retirement Plans Group to Massachusetts Mutual Life Insurance Company, a leading mutual life insurance company
20-Aug-12
$7.3 billion
Target:
Coventry Health Care Inc.
Acquiror:
Aetna
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
27-Apr-12
$NA
Target:
Merlin Securities LLC
Acquiror:
Wells Fargo & Company
Advised Merlin Securities LLC, a leading prime brokerage company in the US, on its sale to Wells Fargo
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
08-Aug-11
$11.0 billion
Target:
Coal and Allied Industries Limited
Acquiror:
Rio Tinto Limited / Mitsubishi Corporation
Advised Coal and Allied Industries Limited, an Australian based coal mining company, in relation to an acquisition proposal from Rio Tinto Limited and Mitsubishi Corporation to acquire all the outstanding shares in the company not already held by Rio Tinto and Mitsubishi
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
08-Jun-11
$1.7 billion
Target:
Citigroup (selected private equity assets)
Acquiror:
AXA Private Equity
Advised AXA Private Equity, a leading European diversified private equity firm, on its acquisition of a $1.7 billion portfolio of limited partnership interests in private equity buyout funds and a portfolio of direct stakes in companies from Citigroup
23-May-11
$130 million
Target:
Territory Resources Limited
Acquiror:
Exxaro Resources Limited
Advised Exxaro Resources, a diversified South African-based mining company, on its proposed acquisition of Territory Resources, an Australian-based iron producer
13-May-11
$NA
Target:
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
11-Apr-11
~$198 million
Target:
HSBC Afore (subsidiary of HSBC Holdings Plc)
Acquiror:
Principal Financial Group, Inc.
Advised Principal Financial Group, Inc., a leading asset accumulation, asset management and retirement services franchise in the United States and abroad on its acquisition of HSBC Afore, HSBC’s pension business in Mexico
01-Mar-11
$122 million
Target:
Australian Unity Limited
Advised Australian Unity Limited, a leading healthcare, financial services and retirement living mutual organisation, on its A$120 million issue of five year unsecured notes listed on the Australian Stock Exchange